Get started
Author

Gabriel Roberti De Oliveira

Observed names: G. Oliveira, Gabriel R. De Oliveira, Gabriel Roberti de Oliveira, Gabriel Roberti. De Oliveira
ORCID: 0009-0008-6565-7720
Observed ORCID: 0009-0008-6565-7720
OpenAlex ID: A5143419788
Tertiary lymphoid structures harbour stem-like tumour-specific T cells
2026 · Alexander B. Afeyan, Adi Nagler, et al. · Nature · 5
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al. · Clinical Cancer Research · 2
PDF
Dynamic Jaws and Dynamic Couch in Helical Tomotherapy
2009 · F. Sterzing, M. Uhl, et al. · International Journal of Radiation Oncology*Biology*Physics · 2
Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma
2026 · Prathyusha Konda, Alexandra J. Wakolbinger, et al. · Nature Communications · 1
PDF
Rapid on-site evaluation for head and neck lesions
2023 · Gabriel Roberti de Oliveira, Mauro Saieg · Diagnostic histopathology · 1
Polycomb scaffolding subunit EED supports the SCLC neuroendocrine identity and EGFR-mutant LUAD-to-SCLC transformation
2026 · Yixiang Li, Yasmin N. Laimon, et al. · Journal of Clinical Investigation
Supplementary Table S9 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S3 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S6 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S4 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S7 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S11 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S10 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Figure S1 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Data from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S8 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S5 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Figure S5 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Figure S2 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S2 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Figure S3 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S1 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Figure S4 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Abstract 3528: EED drives the small cell lung cancer neuroendocrine phenotype in lung cancer histological transformation
2026 · Yixiang Li, Yasmin N. Laimon, et al. · Cancer Research
Abstract B018: Profiling the ccRCC surfaceome reveals SEMA5B as a potential therapeutic membrane target
2026 · Yanyan Hu, Khanh Nguyen, et al. · Cancer Research
Works count: 30
Citation count: 11
H-index: 2
I10-index:
Year
Topic
Type